FGEN: FibroGen, Inc Company Profile & Statistics

About

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

Info & Links

CEO

Thane Wettig

Headquarters

350 Bay Street, Suite 100, #6009
SAN FRANCISCO, CA 94158, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

225

FibroGen, Inc Statistics

Valuation Measures

Market Capitalization²

26.98M

Enterprise Value

66.79M

Enterprise Value/EBITDA(ttm)

-0.58

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

0.43

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

87.90%

Operating Margin(ttm)

-67.66%

Profit Margin(ttm)

20.60%

Return on Equity(ttm)

Return on Invested Capital(ttm)

90.24%

Return on Assets(ttm)

-36.17%

Income Statement

Revenue(ttm)

7.00M

Revenue Per Share(ttm)

0.07

Gross Profit(ttm)

12.53M

EBITDA(ttm)³

-114.34M

Net Income Available to Common(ttm)

-10.01M

Diluted EPS(ttm)

-1.23

Share Statistics

Beta (5Y Monthly)

0.75

52-Week Change

-76.34%

S&P 500 52-Week Change

9.20%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

101.04M

Dividend Yield

0.00%

Float⁴

98.78M

% Held by Insiders

1.98%

% Held by Institutions

72.71%

Balance Sheet

Total Cash(mrq)

33.61M

Total Cash Per Share(mrq)

0.33

Total Debt(mrq)

73.42M

Total Debt/Equity(mrq)

-37.38%

Current Ratio(mrq)

2.02%

Quick Ratio(mrq)

1.16%

Book Value Per Share(mrq)

-1.94

Cash Flow

Operating Cash Flow Per Share(ytd)

0.03

Free Cash Flow(ytd)

2.70M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

FGEN

FibroGen, Inc

FibroGen, Inc Profile